News from Decision Resources, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 12, 2013, 09:58 ET Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while most of...


Nov 07, 2013, 11:30 ET Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...


Nov 06, 2013, 10:15 ET A Balanced Risk-Benefit Profile Will Propel Orexigen/Takeda's Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients

 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that novel...


Nov 05, 2013, 10:47 ET Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that with...


Nov 04, 2013, 09:00 ET Through 2022, Growth in the Neuropathic Pain Drug Market Will be Constrained by the Genericization of Sales-Leading Agents from Eli Lilly/Shionogi, Endo/Grunenthal and Pfizer

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the loss of...


Oct 31, 2013, 10:19 ET Surveyed EU5 Medical Oncologists Prescribe Iressa or Tarceva as a First-Line Treatment to an Average of 70 Percent of Their Confirmed EGFR-Mutation Positive NSCLC Patients

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...


Oct 30, 2013, 09:00 ET The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022

  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the systemic...


Oct 29, 2013, 10:00 ET In Russia, the Use of Premium-Priced Novel Agents Will Expand the Acute Coronary Syndrome Market Through 2017

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012...


Oct 29, 2013, 09:00 ET The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the Projected Launch of Eli Lilly's Solanezumab

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, projects that the market...


Oct 28, 2013, 09:00 ET The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to...


Oct 28, 2013, 09:00 ET Despite Formulary Coverage of Several Biologic Agents for Rheumatoid Arthritis in Argentina and Mexico, Low Biologic Treatment Rates Characterize These Markets

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


Oct 24, 2013, 10:31 ET Approximately Half of Surveyed EU5 Rheumatologists Report Increased Prescribing of RoActemra for RA Due to Superior Efficacy Over Humira in a Head-to-Head Clinical Trial

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results...


Oct 23, 2013, 09:00 ET Increasing Affluence and Legislative Reforms are Transforming Poland's Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Poland's...


Oct 23, 2013, 08:00 ET Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through...


Oct 22, 2013, 10:00 ET Maxalt/Maxalt MLT is the Most Commonly Prescribed Branded Triptan Used by Newly Diagnosed Migraine Patients in the United States

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through...


Oct 21, 2013, 11:00 ET In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug...


Oct 17, 2013, 10:33 ET For Treatment of Rheumatoid Arthritis, About One-Half of Surveyed U.S. Rheumatologists and Payers Indicate that Xeljanz Has Efficacy Comparable to TNF-alpha Inhibitors

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately...


Oct 17, 2013, 09:00 ET Despite the Expected Launch of Eight New Therapies, Growth in the Hospital-Treated MRSA Drug Market Will Be Constrained by Entry of Generic Linezolid and Daptomycin

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


Oct 16, 2013, 11:00 ET Biopharma New Product Launches Originating from In-Licensing Deals Have Increased Dramatically Over the Past Decade

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biopharma...


Oct 16, 2013, 09:00 ET The Type 2 Diabetes Market Will Nearly Double, Increasing from $27 Billion in 2012 to $47 Billion in 2022

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...